BLRX BioLine Rx
- 0.632
- -0.020-3.04%
BioLine Rx News
Express News | BioLineRx To Present Poster On Economic Model Data For APHEXDA Today At ISPOR 2024
Buy Rating on Bioline RX Ltd for Breakthrough Stem Cell Mobilization and Enhanced Apheresis Efficiency
Express News | BioLineRx Announces Poster Presentation On Apheresis Center Efficiency And CXCR4 Antagonists Including APHEXDA At ASFA 2024 Annual Meeting Apr. 17-19
Express News | BioLineRx Has Drawn-down The Second Tranche Of $20M Under Its Previously Announced $40M Non-Dilutive Debt Financing Agreement With Funds And Accounts Managed By Blackrock
Express News | BioLineRx Shares Are Trading Lower After the Company Announced a $6 Million Registered Direct Offering
BioLineRx to Raise $6M Through a Direct Offering
BioLineRx Announces $6M Registered Direct Offering Of 7.5M ADS And Warrants To Purchase Up To An Aggregate Of 7.5M ADSs, At A Combined Purchase Price Of $0.80 Per ADS And Accompanying Warrant
BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX) ("BioLineRx" or the "Company"), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced t
BioLineRx Ltd. (NASDAQ:BLRX) Q4 2023 Earnings Call Transcript
BioLine RX Price Target Maintained With a $21.00/Share by HC Wainwright & Co.
BioLine RX Price Target Maintained With a $21.00/Share by HC Wainwright & Co.
Earnings Call Summary | BioLine Rx(BLRX.US) Q4 2023 Earnings Conference
The following is a summary of the BioLineRx Ltd. (BLRX) Q4 2023 Earnings Call Transcript:Financial Performance:BioLineRx reported total revenues of $4.8 million in 2023, attributed to the Gloria Biosc
Express News | BioLine Rx Q4 EPS $(0.15) Beats $(0.22) Estimate, Sales $4.80M
Express News | BioLineRx Shares Are Trading Lower After the Company Reported FY23 Financial Results
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
GainersStoke Therapeutics (NASDAQ:STOK) stock increased by 80.2% to $11.71 during Tuesday's pre-market session. The market value of their outstanding shares is at $522.8 million. As per the press rele
BioLine RX 2023 Rev $4.8M >BLRX
BioLine RX 2023 Rev $4.8M >BLRX
Express News | BioLineRx FY23 Total Revenues $4.8M, EPS $(0.06)
Earnings Scheduled For March 26, 2024
Companies Reporting Before The Bell • bluebird bio (NASDAQ:BLUE) is likely to report quarterly loss at $0.66 per share on revenue of $16.68 million. • AIM ImmunoTech (AMEX:AIM) is estimated to report
Biolinerx Q4 2023 Earnings Preview
Earnings Preview For BioLine Rx
BioLine Rx (NASDAQ:BLRX) is set to give its latest quarterly earnings report on Tuesday, 2024-03-26. Here's what investors need to know before the announcement.Analysts estimate that BioLine Rx will r
Earnings Week Ahead: Walgreens Boots Alliance, Carnival, GameStop and More
BioLineRx to Report 2023 Annual Financial Results on March 26, 2024
Analysis
Price Target
No Data
